Partially Oxidized Alginate as a Biodegradable Carrier for Glucose‐Responsive Insulin Delivery and Islet Cell Replacement Therapy
Name
nihms-1850001.pdf
Description
Accepted version
Size
1.21 MB
Format
Adobe PDF
Checksum (MD5)
2da377770e9490e799e174edc7c8a998
Author(s)
Volpatti, Lisa R
Bochenek, Matthew A
Facklam, Amanda L
Burns, Delaney M
MacIsaac, Corina
Morgart, Alexander
Walters, Benjamin
Langer, Robert
Anderson, Daniel G
Date Issued
January 2023
Journal
Advanced Healthcare Materials
Publisher
Wiley
Citation
Volpatti, Lisa R, Bochenek, Matthew A, Facklam, Amanda L, Burns, Delaney M, MacIsaac, Corina et al. 2023. "Partially Oxidized Alginate as a Biodegradable Carrier for Glucose‐Responsive Insulin Delivery and Islet Cell Replacement Therapy." Advanced Healthcare Materials, 12 (2).
Version
Author's final manuscript
Abstract
Self‐regulated insulin delivery that mimics native pancreas function has been a long‐term goal for diabetes therapies. Two approaches towards this goal are glucose‐responsive insulin delivery and islet cell transplantation therapy. Here, biodegradable, partially oxidized alginate carriers for glucose‐responsive nanoparticles or islet cells are developed. Material composition and formulation are tuned in each of these contexts to enable glycemic control in diabetic mice. For injectable, glucose‐responsive insulin delivery, 0.5 mm 2.5% oxidized alginate microgels facilitate repeat dosing and consistently provide 10 days of glycemic control. For islet cell transplantation, 1.5 mm capsules comprised of a blend of unoxidized and 2.5% oxidized alginate maintain cell viability and glycemic control over a period of more than 2 months while reducing the volume of nondegradable material implanted. These data show the potential of these biodegradable carriers for controlled drug and cell delivery for the treatment of diabetes with limited material accumulation in the event of multiple doses.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Biological Engineering
Harvard-MIT Program in Health Sciences and Technology
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution-Noncommercial-ShareAlike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1002/adhm.202201822
